Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma

Trial Profile

Phase II Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) in Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Relapsed B Cell Non-Hodgkin Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Vorinostat (Primary) ; Cladribine; Rituximab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 22 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.
    • 22 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Mar 2016 as reported by clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top